Melissa Hollo: Anemia and the Gender Gap in Healthcare
Melissa Hollo, Director of Project Management at hc1 and Licensed Independent Clinical Social Worker, shared a post on LinkedIn:
“Why is it still acceptable for women to ‘feel tired’ due to anemia, while men with the same hemoglobin level are more likely to receive evaluation and treatment?
For years, there has been a different thought process surrounding anemia in women compared to men, often attributed to menstruation.
However, should ‘normal’ monthly blood loss mean women are expected to endure lower energy, fatigue, brain fog, or poorer health outcomes?
A crucial question arises: Why do men get to feel better than women?
If a hemoglobin level of 13 is significant for identifying anemia risk and improving outcomes in men, why wouldn’t we assess women with the same standard?
Assessment and treatment should be equitable, regardless of sex.
Early identification is essential, particularly in women’s health, maternal health, and surgical care.
This is where technology and AI can help eliminate bias from clinical decision-making.
Standardized assessments ensure patients are identified based on risk and evidence, rather than outdated assumptions.
Women deserve to feel well too.”

Other posts featuring Melissa Hollo on Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI